• 3070 Bristol Pike, Suite 112, Bensalem, PA 19020

  • Call Us: (215) 638-4847 |

    Fax: (215) 638-4867

Tenax Therapeutics, Inc. (NASDAQ: TENX)

Case Details

Join The Class Action

This lawsuit is for anyone who acquired securities in Tenax Therapeutics, Inc. (NASDAQ: TENX) from November 13, 2023 through August 7, 2026.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, in the prospectus to the Company’s IPO and throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling investors that the Company’s heart drug candidate, TNX-103, was more effective than the Company knew to be the case.

On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 “did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score.” On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Tenax Therapeutics, Inc. (NASDAQ: TENX) from November 13, 2023 through August 7, 2026 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.